febuxostat has been researched along with clomipramine in 2 studies
Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (clomipramine) | Trials (clomipramine) | Recent Studies (post-2010) (clomipramine) |
---|---|---|---|---|---|
818 | 133 | 710 | 2,929 | 541 | 304 |
Protein | Taxonomy | febuxostat (IC50) | clomipramine (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.034 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.071 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.241 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.091 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.005 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.053 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.707 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 3.9465 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.091 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.413 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.005 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0505 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.7065 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.005 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.17 | |
D(1A) dopamine receptor | Homo sapiens (human) | 1.113 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.0678 | |
Histamine H2 receptor | Homo sapiens (human) | 2.049 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.18 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.067 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.034 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.005 | |
5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.005 | |
5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.005 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.005 | |
5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | 0.005 | |
Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.0002 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.035 | |
5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | 0.005 | |
5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | 0.005 | |
5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | 0.005 | |
Histamine H1 receptor | Homo sapiens (human) | 0.085 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.139 | |
5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.005 | |
Trypanothione reductase | Trypanosoma brucei brucei | 3.4 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.239 | |
Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 0.72 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.245 | |
Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | 9 | |
Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.7615 | |
5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 0.005 | |
Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 1.362 | |
5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.005 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for febuxostat and clomipramine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for febuxostat and clomipramine
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |